RenewCO2's electrocatalytic carbon utilization (eCUT-FA) converts industrial CO2 directly into formic acid — and, in the roadmap, monoethylene glycol and ammonia — in a single step, with no precious metals, at lower energy cost than the CO2→CO→chemicals pathway pursued by Twelve, Oxygencats, and Korean chaebol R&D groups. The wedge is a JDA with Ohmium (Arne Ballantine's prior PEM electrolyzer company) that piggy-backs on Ohmium's Indian manufacturing to compress capex and process-development timelines competitors must fund internally — a combination that lead investor Neal Dikeman (ETV) argues makes the eCUT process “dramatically cheaper than fossil” at sub-1.5¢/kWh renewable power in the best markets (recWRbBssB05B4M4i, 2026-06-10).
Validation is concentrated but real: DNP (Japan, materials/coatings, 100+ factories) is a strategic investor and named customer, with equipment deployment targeted for 2029 and plans to continue through Series A (recYwBrAMxpf2GwzN, 2026-06-08); La Defense's Charlie Chang — a 7–8 year Bloom Energy Korea relationship — is closing a small check plus commercial access to SK, LG, and Kumho (reccmZOW87wGDMS9Q, 2026-06-17); ETV re-cut the closing documents so StoryHouse qualifies as a “major investor” with co-sale, ROFR, information, preemptive, and pro-rata rights through the Series A (recUDwr0VHDwlQY5M, 2026-06-19). StoryHouse Fund II committed $750K in a two-pronged structure — 75% priced at $16M pre / $22M post, 25% on a convertible at an $80M cap with 20% discount and 7.5% interest — for ~3% ownership. The first commercial-scale eCUT electrolyzer (0.5 tonne CO2/day) is targeted for 2027.
The addressable market is real and growing at a double-digit clip, but the industry consensus is that electrochemical CO2-to-chemicals routes scale meaningfully post-2030 — which aligns with RenewCO2's 2027 first commercial electrolyzer and 2029 DNP factory deployment. Tailwinds: carbon-price mechanisms in the EU/UK/California, corporate scope-3 mandates, and — per Neal Dikeman — sub-1.5¢/kWh renewable electricity in the best markets (Saudi Arabia, India) that flips fossil-vs-electrochemical unit economics.
| Player | Positioning | Funding | Edge |
|---|---|---|---|
| RenewCO2 | Single-step electrocatalytic CO2→formic acid (eCUT-FA); no precious metals; Ohmium JDA for PEM stack & India manufacturing | $13M+ equity, $9M+ non-dilutive | — |
| Twelve | CO2→CO→SAF and chemicals; two-step process; SAF-led commercialization | Well-capitalized late-stage | Capital depth & SAF offtake pipeline; but higher process complexity per DNP diligence |
| Avantium | Dutch CO2/plant-based FDCA plastics; longer track record; broader competitor set per CB Insights | Publicly traded | Public-market access & operating commercial plants |
| OxCCU / Oxygencats | Electrochemical CO2→chemicals; higher energy cost per DNP evaluation (recYwBrAMxpf2GwzN) | Early-stage | Oxford spin-out; academic pedigree; DNP evaluated and rejected on energy cost |
| SK / LG / Samsung internal R&D | Korean chaebols pursuing CO2-to-chemicals internally; can deploy capital rapidly if they commit | Internal balance sheet | Scale & downstream chemical asset base; La Defense flags as fastest speed-to-market risk |
Moat: Single-step CO2-to-formic-acid conversion (bypassing the CO intermediate) combined with the Ohmium JDA shortcuts capex and process-engineering timelines competitors must fund and staff themselves — a moat Charlie Chang (La Defense) explicitly cited as his primary conviction driver alongside Arne's operator track record.
The traction story is not revenue — it is anchored customer commitment plus non-dilutive validation. DNP is both a check and a factory pipeline; Ohmium's JDA is a manufacturing partner, not just an LOI; $9M+ from DOE/NSF/DARPA/Breakthrough Energy is meaningful third-party technical diligence. The 2027 first-electrolyzer milestone is the gate to Series A credibility.
Likely acquirers cluster in three buckets: (1) chemical majors like LyondellBasell, Dow, and Braskem needing decarbonized MEG feedstock for PET; (2) industrial gas companies (Air Liquide, Linde) that already package CO2 capture and want a downstream utilization play; (3) Asian strategics — DNP itself (with Coca-Cola PET subsidiary demand per 2026-06-08 note), or the SK / LG / Kumho block that Charlie Chang plans to introduce commercially. Return math: at ~3% ownership and typical carbon-tech strategic exit multiples, the $750K check has plausible paths to 10–40× contingent on Series A execution, first commercial electrolyzer proving out, and DNP's 2029 factory deployment triggering.
Good call and discussion with Neil.
We agreed that, for simplicity's sake, at the end of July, if there is still any portion of the round unallocated, we will remove that from the cap table. This will lower the post-money valuation and still increase our ownership, but we'll avoid the need to figure out prorated proportions of the unallocated amounts and have folks re-sign.
The plan for the next two weeks: they will continue discussions already happening with HMC Inc, etc. Not pursue fundraising any further after July 31. Close the round out and lower the post-money valuation by whatever the unallocated portion remains.
Source: Meeting Notes recfYmBVkduL3UAGkETV explained that the documents had drifted from the original term sheet, and StoryHouse had been unintentionally no longer clearly captured by the existing major investor threshold because that threshold had originally been set around DNP's share count.
Rather than naming StoryHouse directly or relying on a side letter, which has not been done for other investors either, Neal said ETV wanted to fix this in the main documents by lowering the threshold so StoryHouse qualifies as a major investor and by adjusting the amendment mechanics so no single investor can change those rights unilaterally, while also avoiding giving any one smaller holder a permanent veto.
His rationale was that hardwiring StoryHouse by name would likely force the same treatment for other small investors and make the documents harder to amend in future rounds, whereas this structure preserves flexibility while still protecting early investors. Neal also confirmed that StoryHouse has the exact same major investor rights package as Knotty Bear, including co-sale, ROFR, information rights, and preemptive rights, and said ETV's intent is not to marginalize smaller investors but to keep everyone treated fairly and informed as the company grows.
Additionally, he proposed that, given the convertible note structure, we should have pro rata rights into the subsequent round beyond the Series A. Overall, this made sense and Neal seems to be a good partner. It may have been preferable to have ourselves explicitly written in the documents, but given Knotty Bear and others do not have this — even though Knotty Bear is investing 4x more than us in this financing — his proposed structure is acceptable.
Source: Meeting Notes recUDwr0VHDwlQY5MLa Defense Investment is a new technology finance company licensed by the Financial Supervisory Service (FSS) of Korea, the same regulator that oversees banks and insurance companies. Higher bar than the typical Korean VC license, requires $10M in paid-in capital, took roughly 12 months. License granted April 2026. Separate entity from La Defense Partners (private equity), separate management, separate funding pools.
Focus: impact investing exclusively. Stage: prefers late stage; RenewCO2 is an explicit exception. Geography: Korea-focused for now due to weak Korean won (10–15% FX headwind out of the gate). Check size: small, investing off balance sheet capital; no fund raised yet. Follow-on: cannot commit to Series A or beyond until a fund is established.
How Charlie met Arne: Charlie knew Arne from Bloom Energy CTO days, connected through Harry O., head of Bloom Energy Korea, roughly 7–8 years ago. Arne and Karin visited Korea toward the end of 2025, and Harry arranged a meeting. That reconnection led to Charlie evaluating RenewCO2 over the past 7–8 months.
Diligence: received data room access; conducted DD sessions with Anders and Arne alongside Dr. Son (Cambridge micro/molecular biology PhD, ex-McKinsey), who served as scientific advisor. Science review was “very convincing.” Some DD questions remain outstanding.
Milestones for the next financing: right personnel in place; all agreements with Ohmium documented and executed; insurance and operational processes established; pilot plant in India initiated; formic acid production launched; ethylene glycol production as a secondary milestone. Charlie believes the Series A needs to happen soon, possibly this year, and noted the company may already be slightly delayed.
Risks: competition — “it's like a race” among 15+ CO2-to-chemical companies; funding — closing the seed and moving quickly to Series A; speed to market — Korean corporates (SK, LG, Samsung) are advanced in this space and can deploy capital fast; India/geopolitical risk present but not primary concern under Modi.
Portfolio parallels: New Light Technologies (PHB bioplastic, Huntington Beach); Cortical Dynamics (Australia, brain monitor targeting Medtronic's OR product); Gentium Partners VC (prior impact/climate fund, 28 portfolio companies, sold August 2024, retained portfolio).
Terms/status: check size “very small,” “diminutive”; investing off balance sheet capital; documentation received from lawyers this morning; not yet signed; DD questions still outstanding with Anders. Single check only — cannot reserve for Series A until a fund is established. Trying to bring in one or two Korean corporate co-investors (paint or chemical company) to form an investment club.
Value: capital contribution is not the point — “our contribution is going to be very small.” The value is commercial door-opening with Korean corporates (SK, LG, Kumho) at commercialization, mirroring the role played for New Light Technologies in Korea.
Source: Meeting Notes reccmZOW87wGDMS9QTwo independent co-investor references, both organized around Arne Ballantine, both closed conversations with signed or imminent commitments: